Molecule News and Research

RSS

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis, Inc., a La Jolla, Calif.-based life science company, has been issued patents in Japan, China and India for its innovative technology that captures the unique signals of approved drugs at the atomic level and then delivers the signal in a solution to treat serious illnesses. The technology, which also has U.S., Canadian and Australian patents, promises to transform the treatment of diseases, including those for which there are no known cures, such as brain cancer.

10 Jun 2010

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

10 Jun 2010

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

Researchers from GE Global Research announced today that they have been awarded a four-year, $4 million grant from the National Institutes of Health, to optimize a new nerve labeling agent and imaging system. In the future, this agent could help surgeons see delicate nerve endings that are prone to damage during certain procedures, such as prostate surgery.

10 Jun 2010

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.

9 Jun 2010

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).

9 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.

9 Jun 2010

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

DSM BioSolutions today announced that it has entered into an agreement with Novacta Biosystems Limited, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

9 Jun 2010

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

TransTech Pharma, Inc and Forest Laboratories, Inc., today announced that TransTech Pharma and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. have entered into a license agreement for the development and commercialization of small molecule compounds discovered and developed by TransTech Pharma.

9 Jun 2010

Researchers decipher how mast cells set immune defense on right track

In the event of an infection, the immune system releases messenger substances. These molecules can either activate immune cells to defeat invading pathogens, or inhibit them to prevent an excessive immune reaction. For this, the immune system has to decide very quickly what mixture of activating and inhibiting messenger molecules leads to a successful defence.

8 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors.

8 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

Tel Aviv University discovers ancient switch in plants that could halt cancer metastasis

Although plants and animals are very different organisms, they share a surprising number of biological mechanisms. A plant biologist at Tel Aviv University says that one of these mechanisms may be the answer for turning off cancer growth in humans.

8 Jun 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC Therapeutics, Inc. today announced the receipt of a $5.4 million Seeding Drug Discovery Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers.

7 Jun 2010

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

O2h (Ahmedabad, India) is pleased to announce the signing of an agreement with Karyopharm Therapeutics, Inc. (Newton, Massachusetts, USA) under which O2h will provide Karyopharm discovery services to advance Karyopharm's lead small molecule program toward the nomination of a development candidate.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

Molecule News and Research

Nativis awarded patents in Japan, China, India for drug signal technology

Updated clinical data from SNSS's Phase 2 clinical trial of voreloxin

GE Global Research awarded $4M grant to optimize new nerve labeling agent and imaging system

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

DSM commences cGMP-manufacturing of Novacta's C. difficile compound

TransTech Pharma, Forest Laboratories Holdings agree to develop and commercialize GKA compounds

Researchers decipher how mast cells set immune defense on right track

Research findings open door to development of new therapies for lymphomas, leukemias

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Tel Aviv University discovers ancient switch in plants that could halt cancer metastasis

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News